Japan Seasonal Flu Vaccine Market

Japan Seasonal Flu Vaccine Market Size Report – In a Glance

As per the survey report on Japan seasonal flu vaccine market, the market is expected to foresee a CAGR value of 7.1% during 2025-2035, and further generate a market size of USD 597.8 Million by the end of 2035. In 2024, the market size was value at USD 260.7 Million revenue.

• The Japan seasonal flu vaccine market’s growth is driven by rising awareness about vaccination and government promoting vaccination.
• KDMI analyst’s growth analysis foresees high development and storage as the restraint for Japan seasonal flu vaccine market.

Japan Seasonal Flu Vaccine Market Analysis

A seasonal flu vaccine also known as the influenza vaccine is designed to protect people against seasonal flu which occur especially during monsoon season. This vaccine boosts immunity of a person to fight against influenza bacteria and reduce the severity of infection. Seasonal vaccine is categorized as Injectable and Intranasal. The market growth is influenced by the growing awareness about vaccination and government initiatives promoting preventive steps. According to the report represented by Japan Health Policy NOW, the total influenza vaccine coverage rate is 50.2%, in which half of the population was aged above 60 years. Sinovac, Changsheng, and Aleph Biomedical are some of the significant participants in the Japan seasonal flu vaccine market.

Japan Seasonal Flu Vaccine Market Growth Drivers and Restraints

Growth Drivers

• Government support and National Immunization programs – The Japanese government plays important role in promoting seasonal flu vaccines by imposing stringent policies and public health initiatives that drives the growth of Japan seasonal flu vaccine market. As per the nationwide survey report, the mean estimated vaccination uptake across Japan was 17.9%. This shows the government policies and regulations under Vaccination Act is promoting vaccination drive by providing subsidies or fully cover cost of influenza vaccine for high-risk groups like senior-citizens and children below age 5 years. These government programs not only reduce out-of-pocket cost but also encourages people in taking vaccination. Moreover, public health service programs and awareness campaigns during flu season, lead to the greater demand for seasonal vaccines, which contributes in the market growth.
• Advancement in Vaccine technology – With the continuous advancement in healthcare and medical sector, the innovations in upgrading and building effective vaccines play major role in the Japan seasonal flu vaccine market. This integration of latest technology ensures enhanced effectiveness and convenience of seasonal immunization in Japan. Moreover, the adoption of cell-based and recombinant vaccine technologies has further boosted the demand for vaccination in the country, leading to overall market growth. Japan is also increasingly investing in developing universal flu vaccine using mRNA technology.

Restraints

• High development and storage costs – One of the major restraints in the Japan seasonal flu vaccine market is the costs involved in the development of highly-effective vaccines. The production, marketing, and distribution costs leads discouragement amongst population, especially for cost-conscious consumers. As the influenza viruses spread rapidly, requires quick and efficient solution to it which demands higher investment in research and development. Further, storing space and costs challenges the market growth, due to vaccine storage is a critical process with the aim of maintaining its chemical properties.

Japan Seasonal Flu Influenza Vaccine Market Segmentation

Our experts at KD Market Insights have segmented the Japan seasonal flu influenza market research report as:

Analyst’s Observation on Japan Seasonal Flu Influenza Market Recent Developments

Over the years, the experts at KD Market Insights have been observing the recent developments associated with Japan seasonal flu vaccine market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

Certainly, Osivax and KM Biologics has entered into exclusive license option agreement for the development, manufacturing, and commercialization of Osivax’s broad-spectrum “universal” influenza vaccine in Japan. This vaccine provides protection against highly mutating respiratory viruses.

Daiichi Sankyo has recently launched FluMist Intranasal Spray in Japan as the country’s first nasally administered vaccine to provide protection against seasonal influenza. The company had planned to supply approximately 1.3 million doses during its distribution on October 3, 2024.

Japan Seasonal Flu Vaccine Market Competitive Landscape

Some of the significant participants who top the Japan seasonal flu vaccine market share:

• GSK

• Sinovac
• Changsheng
• CCBIO
• Aleph Biomedical
• Sanofi
• Lanzhou Institute Of Biological Product
• Siobp
• Hualan Bio
• Tianyuan Bio-Pharma
• Vaxtec
• Hissen
• Abbott
• Novartis